Copenhagen, 26 June 2015 – Zealand announces results from a clinical Phase I trial with a single-dose version of its novel, stable glucagon analogue, ZP4207. ZP4207, invented and wholly-owned by Zealand, is suited for liquid formulation and has in preclinical studies shown promising potential as a more convenient ready-to-use rescue pen for the treatment of severe hypoglycemia. Severe hypoglycemia is an acute, life threatening condition affecting both Type 1 and Type 2 diabetes patients on insulin therapy when their blood sugar levels drop too low.
Zealand initiated the ZP4207 single-dose Phase I trial in November 2014 as a two-part study to evaluate safety and tolerability in both healthy volunteers and Type 1 diabetes patients. The enrollment and treatment of 64 healthy volunteers and 20 patients with Type 1 diabetes was completed ahead of schedule. Based on the results from the trial, Zealand will now progress the development of ZP4207 for severe hypoglycemia towards the next clinical phases.
In parallel with the development of ZP4207 as a single-dose rescue treatment, Zealand is also evaluating a multiple-dose version of ZP4207 in a clinical Phase IB trial for the treatment of mild to moderate hypoglycemia including its potential use in a dual-hormone artificial pancreas pump.
Read more: https://globenewswire.com/news-release/2015/06/26/747696/0/en/Phase-I-trial-results-for-Zealand-s-glucagon-analogue-ZP4207-support-its-further-development-as-a-ready-to-use-rescue-treatment-for-severe-hypoglycemia-in-diabetes-patients-on-insu.html?print=1